While we anticipate that Praxbind ® will be rarely used in clinical practice, the availability of a specific reversal agent has the potential to give physicians and patients added confidence in choosing Pradaxa ®.â âWith this approval, Boehringer Ingelheim is again leading the evolution of anticoagulation care, as we did with the introduction of Pradaxa ®. ÂWe are very pleased to offer Praxbind ®, the first specific reversal agent for a novel oral anticoagulant, now approved by the FDA,â said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. This Smart News Release features multimedia. 4 Praxbind ® is indicated for patients treated with Pradaxa ® (dabigatran etexilate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. Food and Drug Administration (FDA) granted approval of Praxbind ® (idarucizumab). If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.Boehringer Ingelheim GmbH announced the U.S. The use of the eHealthMe site and its content is at your own risk. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect.
Different individuals may respond to medication in different ways. Our phase IV clinical studies alone cannot establish cause-effect relationship.
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.ĭISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. Our analysis results are available to researchers, health care professionals, patients ( testimonials), and software developers ( open API). Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. We study millions of patients and 5,000 more each day. With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials.
0 kommentar(er)
